Organogenesis' Q2 Operating Income Fell 50%, Lowers Annual Guidance

  • Organogenesis Holdings Inc's ORGO Q2 FY22 sales reached $121.4 million, down 1% Y/Y, slightly ahead of the consensus of $120.90 million.
  • The decrease was driven by a 35% decrease in Surgical & Sports Medicine products, partially offset by a 2% increase in Advanced Wound Care products.
  • The gross margin improved from 76% to 78%. Operating income fell almost 50% to $11.9 million.
  • Adjusted net income reached $11.3 million compared to $20.3 million a year ago. Adjusted EBITDA was $18.6 million, a decrease of 26% Y/Y.
  • Guidance: For FY22, Organogenesis forecasts sales of $465-$490 million, a decrease of approximately 1% - an increase of 5% Y/Y and 2% - 7% on an adjusted basis, and compared to the consensus of $494.15 million.
  • The company forecasted sales of $485-$515 million in May.
  • The outlook includes sales from Advanced Wound Care products of $435-$456 million, down from the previous outlook of $455-$481 million.
  • The company reaffirmed Surgical & Sports Medicine product sales of $30-$34 million.
  • The company expects an adjusted net income of $33-$43 million and adjusted EBITDA of $60-$74 million, down from previous guidance of $47.3-$58.8 million and $79.9-$95.3 million, respectively.
  • Price Action: ORGO shares are down 21.80% at $4.70 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsPenny StocksGuidanceHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!